Since it may be two or three years until Celgene’s oral anti-myeloma novel therapy agent, pomalidomide, is approved by the FDA and widely available, patients with relapsed and/or refractory multiple myeloma may want to consider getting involved in a pomalidomide related clinical study.
If you have tried Revlimid and it is no longer working you may be eligible for this new study: Pomalidomide, Cyclophosphamide and Prednisone (PCP) in Patients With Multiple Myeloma (MM) Relapsed and/or Refractory to Lenalidomide.
Pomalidomide just may be the most promising new anti-myeloma drug out there. It is an Italian sponsored study, but there may be some approved locations in the United States. Get this info to your oncologist right away to see if you qualify for inclusion in the study–and if it is available to U.S. citizens. If it is, please let me know–I may consider this one myself!
Feel good and keep smiling! Pat